Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436338 | 1.00 | CYP19A1 (0.36) | CYP19A1DAOMAOAMAOBGRM1 | |
| SCHEMBL12289430 | 1.00 | CYP19A1 (0.36) | CYP19A1DAOMAOAMAOBGRM1 | |
| SCHEMBL10706120 | 0.93 | CYP19A1 (0.33) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL10676307 | 0.93 | DAO (0.40) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL10017472 | 0.93 | CYP19A1 (0.33) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL10485940 | 0.93 | CYP19A1 (0.33) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL10676302 | 0.93 | DAO (0.40) | CYP19A1DAOMAOAMAOB | |
| SCHEMBL23133729 | 0.84 | — | — | |
| SCHEMBL21946982 | 0.84 | — | — | |
| SCHEMBL21961817 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| WO-2022026823-A1 | CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20180200252-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | SIGNAL PHARM LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-9974786-B2 | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3- B]pyrazin-2(1H)-one, a solid form there of and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| EP-2837623-A1 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2009076747-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | WO | disclosed |
| WO-2007073934-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-5716543-A | GOOD TEMPERATURE BEHAVIOR OF NEMATIC PHASE; SOLUBILITY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | CYP19A1 3772/4885DAO 4103/4885MAOA 4014/4885 |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP19A1 3955/4885DAO 2629/4885MAOA 3230/4885 |
| US-10894040-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | CYP19A1 2995/4885DAO 4768/4885MAOA 3191/4885 |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | CYP19A1 1255/4885DAO 254/4885MAOA 227/4885 |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | CYP19A1 2044/4885DAO 2644/4885MAOA 1847/4885 |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885DAO 2401/4885MAOA 3256/4885 |
| US-20180200252-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | CYP11B2, CYP27A1, CYP11B1 | CYP19A1 245/4885DAO 2250/4885MAOA 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.